Blackstone Life Sciences is providing Apogee Therapeutics with up to $1.3 billion in non-dilutive financing, which the biotech will apply to a key test of its lead drug candidate in atopic dermatitis. The long-acting antibody also has potential applications in asthma and eosinophilic esophagitis.
The post Apogee’s Royalty Deal With Blackstone Will Fund Pivotal Test in Eczema and More appeared first on MedCity News.
